Mouser Electronics Brings Cutting-Edge Innovations to PSECE 2025

Mouser Electronics Brings Cutting-Edge Innovations to PSECE 2025

MANILA, Philippines, Oct. 24, 2025 /PRNewswire/ -- Mouser Electronics, Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, is excited to announce its...

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug...

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors Dr. Fain brings over 35 years of strategic and start-up expertise Extensive experience in the Cardiovascular space particularly in active implants Led multiple successful...

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for...

Toshiba's Heavy Ion Therapy System CI-1000 Wins Minister of Economy, Trade and Industry Award and GOOD DESIGN GOLD AWARD at GOOD DESIGN AWARD 2025

Toshiba's Heavy Ion Therapy System CI-1000 Wins Minister of Economy, Trade and Industry Award and GOOD DESIGN GOLD AWARD at GOOD DESIGN AWARD 2025

-Four designs awarded GOOD DESIGN AWARD- KAWASAKI, Japan, Oct. 22, 2025 /PRNewswire/ -- Toshiba Group has announced that its heavy ion therapy system CI-1000 was honored with a GOOD DESIGN GOLD AWARD and the highly regarded Minister of Economy,...

CAAS Introduces Rear-Wheel Active Steering Technology to Upper Mass-Market EVs in China

CAAS Introduces Rear-Wheel Active Steering Technology to Upper Mass-Market EVs in China

WUHAN, China, Oct. 21, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that with the rapid growth of automotive...

MMA Global Launches Bold New Era as the Marketing + Media Alliance, Advancing Marketers' Ability to Create Value

MMA Global Launches Bold New Era as the Marketing + Media Alliance, Advancing Marketers' Ability to Create Value

MMA's next chapter outlines what it means to lead proven marketing transformation, powered by groundbreaking, award-winning, CMO-validated models, frameworks, and knowledge SINGAPORE, Oct. 21, 2025 /PRNewswire/ -- MMA Global, Inc., the global...

SM Investments certified as a Great Place to Work® in 2025

SM Investments certified as a Great Place to Work® in 2025

PASAY CITY, Philippines , Oct. 20, 2025 /PRNewswire/ -- SM Investments Corporation (SM Investments), the parent company of the SM group, has been certified as a Great Place to Work for 2025 by the global authority on workplace culture, Great Place...

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 38
  • menu
    menu